Results 131 to 140 of about 483,027 (406)

Strategies to reduce the cancer burden and improve access to effective and affordable cancer interventions in Europe

Molecular Oncology, Volume 19, Issue 6, Page 1553-1560, June 2025.
Comprehensive cancer centre (CCCs) and CCCs of Excellence (CCCoE) integration in healthcare. Through outreach to surrounding community hospitals, CCCs enable wider access to top‐clinical cancer treatments and care, thereby facilitating the swift enrolment of patients into data‐rich clinical trials (PI‐initiated trials testing new concepts, drug ...
Anton Berns, Ulrik Ringborg, Julio Celis, Bengt Jönsson, Michael Baumann   +4 more
wiley   +1 more source

Certain amplified genomic-DNA fragments (AGFs) may be involved in cell cycle progression and chloroquine is found to induce the production of cell-cycle-associated AGFs (CAGFs) in Plasmodium falciparum [PDF]

arXiv, 2015
It is well known that cyclins are a family of proteins that control cell-cycle progression by activating cyclin-dependent kinase. Based on our experimental results, we propose here a novel hypothesis that certain amplified genomic-DNA fragments (AGFs) may also be required for the cell cycle progression of eukaryotic cells and thus can be named as cell ...
arxiv  

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

Molecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski, Molly R. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana T. Amaral, Juan Diaz‐Martin, David S. Moura, Javier Martin‐Broto, Ali Alsaadi, Donald M. Salter, Ailsa J. Oswald, Graeme Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton   +19 more
wiley   +1 more source

Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance [PDF]

, 2015
Seliciclib (R-Roscovitine) was identified as an inhibitor of CDKs and has undergone drug development and clinical testing as an anticancer agent. In this review, the authors describe the discovery of Seliciclib and give a brief summary of the biology of ...
Cavicchi, Laura, Khalil, Hilal S., Mitev, Vanio, Vlaykova, Tatyana, Zhelev, Nikolai   +4 more
core   +4 more sources

Effect of Triptolide on Temporal Expression of Cell Cycle Regulators During Cardiac Hypertrophy

Frontiers in Pharmacology, 2020
Adult mammalian cardiomyocytes may reenter the cell cycle and cause cardiac hypertrophy. Triptolide (TP) can regulate the expressions of various cell cycle regulators in cancer cells.
Jing-Mei Li, Jing-Mei Li, Xi-Chun Pan, Yuan-Yuan Ding, Yang-Fei Tong, Yang-Fei Tong, Xiao-Hong Chen, Ya Liu, Hai-Gang Zhang   +8 more
doaj   +1 more source

The cycline subalgebra of a Kumjian-Pask algebra [PDF]

Proc. Amer. Math. Soc. 145 (2017), no. 5, 1969-1980, 2016
Let $\Lambda$ be a row-finite higher-rank graph with no sources. We identify a maximal commutative subalgebra $\mathcal{M}$ inside the Kumjian-Pask algebra ${\rm KP}_R(\Lambda)$. We also prove a generalized Cuntz-Krieger uniqueness theorem for Kumjian-Pask algebras which says that a representation of ${\rm KP}_R(\Lambda)$ is injective if and only if it
arxiv  

Cyclin D activates the Rb tumor suppressor by mono-phosphorylation

eLife, 2014
The widely accepted model of G1 cell cycle progression proposes that cyclin D:Cdk4/6 inactivates the Rb tumor suppressor during early G1 phase by progressive multi-phosphorylation, termed hypo-phosphorylation, to release E2F transcription factors ...
A. Narasimha, M. Kaulich, Gary S. Shapiro, Y. Choi, P. Sicinski, S. Dowdy   +5 more
semanticscholar   +1 more source

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis

Molecular Oncology, EarlyView.
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach, Nilesh Chatterjee, Kellie Spahr, Gilberto Serrano de Almeida, Anabel Varela‐Carver, Taimur T. Shah, Mathias Winkler, Hashim U. Ahmed, Charlotte L. Bevan   +8 more
wiley   +1 more source

MAPK phosphorylation of connexin 43 promotes binding of cyclin E and smooth muscle cell proliferation

, 2012
<p>Rationale: Dedifferentiation of vascular smooth muscle cells (VSMC) leading to a proliferative cell phenotype significantly contributes to the development of atherosclerosis.
Best, A.K., Columbus, L., Dunn, C.A., Isakson, B.E., Johnstone, S.R., Koval, M., Kroncke, B.M., Lampe, P.D., Lo, C.W., Mitchell, L.A., Nakamoto, R.K., Peskova, Y., Straub, A.C.   +12 more
core   +1 more source

The Xenopus Suc1/Cks Protein Promotes the Phosphorylation of G2/M Regulators [PDF]

, 1999
The entry into mitosis is controlled by Cdc2/cyclin B, also known as maturation or M-phase promoting factor (MPF). In Xenopus egg extracts, the inhibitory phosphorylations of Cdc2 on Tyr-15 and Thr-14 are controlled by the phosphatase Cdc25 and the ...
Dunphy, William G., Kumagai, Akiko, Patra, Debabrata, Wang, Sophie X.   +3 more
core   +1 more source